Liquid Biopsies – News and Features

A model based on artificial intelligence is able to predict the therapy outcome in 80% of ovarian cancer patients. The tool, named IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy), analyzes various patient clinical features.

In this opinion piece, Neil Ward explores how advances in sequencing could help to provide new insights for rare disease patients.

A liquid biopsy that identifies cell-free DNA as a marker of cancer could improve cancer detection in patients with Li-Fraumeni syndrome, which carries an almost 100 percent lifetime risk of developing cancer.

A team of scientists at Stanford University has taken a look inside the human eye with a new level of detail by using cutting-edge molecular analysis.

The Association for Molecular Pathology has published a set of 13 best practice recommendations for validating and reporting clinical circulating tumor DNA or liquid biopsy assays and their related scientific publications.

A new study on human tissue and plasma shows the blood test may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

Measuring ctDNA could offer a new approach to identifying non-small cell lung cancer patients in greater need of additional treatments during immunotherapy.

Measuring circulating tumor DNA may lead to alternative treatment options and better outcomes for patients with advanced BRAF-negative melanoma, report investigates in The Journal of Molecular Diagnostics.

A new study could help doctors decide the best treatment strategy for patients with lung cancer that has spread beyond the original tumor but has not spread all over the body.

Researchers have shown for the first time that breast milk from breast cancer patients contains tumor DNA, known as circulating tumor DNA (ctDNA). This can be detected through liquid biopsy in breast milk.